{"url_path":"/sec/hoth/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1711786/0001213900-26-060075-index.html","accession_number":"0001213900-26-060075","cik":"0001711786","ticker":"RKTO","issuer_name":"Rocket One Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711786/0001213900-26-060075-index.html","primary_entity_key":"0001711786","primary_entity_name":"Hoth Therapeutics, Inc."},"word_count":164,"has_tables":true,"body_markdown":"** **\n\n**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n10.1#\n \n[Exclusive License Agreement between the Company and Virginia Commonwealth University Intellectual Property Foundation dated May 15, 2026](ea029183701ex10-1.htm)\n\n10.2#\n \n[Exclusive License Agreement between the Company and Virginia Commonwealth University Intellectual Property Foundation dated May 15, 2026](ea029183701ex10-2.htm)\n\n99.1\n \n[Press Release of Hoth Therapeutics, Inc. dated May 19, 2026](ea029183701ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL Document)\n\n \n\n#Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential\nportions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions\n(i) are not material and (ii) is the type that the Company treats as private or confidential.\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: May 21, 2026\n**Hoth Therapeutics, Inc.**\n\n \n \n\n \n/s/ Robb Knie\n\n \nRobb Knie\n\n \nChief Executive Officer\n\n \n\n \n\n3"}